RTP Mobile Logo
Select Publications

Choudhury NJ et al. Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clin Cancer Res 2021;27(10):2920-7. Abstract

Gonzalvez F et al. Mobocertinib (TAK-788): A targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov 2021;11(7):1672-87. Abstract

Minchom AR et al. Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy. ASCO 2021;Abstract 9052.

Ou S-HI et al. Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. ASCO 2021;Abstract 9098.

Park K et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J Clin Oncol 2021;39(30):3391-402. Abstract

Piotrowska Z et al. Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). ASCO 2021;Abstract 9077.

Yang JC-H et al. Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. ASCO 2021;Abstract 9008.

Yasuda H et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5(216):216ra177. Abstract

Zhou C et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol 2021;[Online ahead of print]. Abstract